Health Economics›Leiomyosarcoma›Advanced or metastatic disease subsequent lines of therapy

Advanced or metastatic disease subsequent lines of therapy

Leiomyosarcoma · 6 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 2 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Regorafenib monotherapy Variant #01	—	R 132 655	28d	3.7 mo	—	2	R 265 310 PFS proxy	1
Trabectedin monotherapy Variant #01	—	R 103 351	21d	—	13.7 mo	2	R 206 702 PFS proxy	1
Eribulin monotherapy Variant #01	—	R 22 427	21d	—	12.7 mo	2	R 44 854 PFS proxy	1
Docetaxel and Gemcitabine Variant #01	—	R 6 266	21d	~6.2 mo	—	~9	~R 56 391 PFS proxy · indirect	1
Dacarbazine and Gemcitabine Variant #01	—	R 4 793	14d	—	16.8 mo	13	R 62 314 PFS proxy	1
Dacarbazine monotherapy Variant #01	—	R 2 608	21d	—	13.1 mo	2	R 5 217 PFS proxy	2

6 of 6 regimens shown